Drug Profile
Research programme: Avibody-based imaging agents - Avipep/Sanofi
Alternative Names: 89Zr-AvibodiesLatest Information Update: 28 Aug 2019
Price :
$50
*
At a glance
- Originator Avipep
- Developer Avipep; Sanofi
- Class Imaging agents; Radiopharmaceutical diagnostics
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Unspecified
Most Recent Events
- 28 Aug 2019 No recent reports of development identified for research development in Unspecified(Diagnosis) in Australia
- 13 Jul 2015 Early research in Undefined indication (Diagnosis) in Australia (unspecified route)